Particularly, in a lead optimization perspective, this novel pyrazolo-pyrimidinone scaffold bearing a hydrazide-hydrazone moiety, was probed for its ability to (1) interact with the epidermal growth factor receptor (EGFR) tyrosine kinase and (2) stabilize G-quadruplex DNA structures, currently known as anticancer targets for cancer therapy [35,36,37]. Here, EGFR is linked to cancer.